CD274 and cervical carcinoma: While two clinical studies are currently investigating the effects of anti-PD‐1 (NCT03614949) as well as anti-PD-L1 and anti-CTLA‐4 (NCT03452332) in combination with SBRT for metastatic, persistent or recurrent cervical cancer, two studies are currently examining a possible benefit of added anti-PD‐1 to chemoradiation ([31] and NCT02635360).